Pricing Log in Create free account
Friday 6 November 2026 Export TEVA’s income statement to Excel — free account

Teva Pharmaceutical Industries Ltd.

TEVA Healthcare Drug Manufacturers Specialty & Generic

Teva Pharmaceutical Industries Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $17.3 billion, up 4.32% from fiscal 2024.

Revenue
−1.90%
EPS
−47.2%
Free cash flow
−30.3%
Total debt
−0.43%

Quarter to September 2026, against a year earlier

42.23 0.45 +1.08%
Market cap
$48.7B
P/E
92.6×
Fwd P/E
30.7×
Dividend yield
—
F-score
8/9
Altman Z
0.79
Beneish M
−2.35
Dividend safety
52/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Teva Pharmaceutical Industries Ltd. (TEVA) EV/EBITDA

Alert me on EV/EBITDA

As of 5 November 2026, Teva Pharmaceutical Industries Ltd. (TEVA) trades at a EV/EBITDA of 26.2×. Over the past ten years it has ranged from 0.0× (December 2023) to 968× (September 2023); the current reading is higher than 85% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 12.2× and above the Healthcare sector median of 8.4×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 15.5× (19.92%)
FY2024 19.4× 7.54%
FY2023 18.0× —
FY2022 0.0× —
FY2021 10.0× —
FY2020 0.0× —
FY2019 27.9× 110.11%
FY2018 13.3× —
FY2017 0.0× —
FY2016 19.2× 51.32%

Quarterly newest first

Period EV/EBITDA Change
Sep 2026 25.2× 20.43%
Jun 2026 20.9× 44.05%
Mar 2026 14.5× (6.35%)
Dec 2025 15.5× 53.96%
43 more quarters

Against its own ten years

Low 0.0× High 968×
Ten-year median 12.9×
Current reading's percentile 85

EV/EBITDA against peers

Company EV/EBITDA
ZTS Zoetis Inc. compare 10.7×
TAK Takeda Pharmaceutical Co. compare 11.2×
HLN Haleon PLC Sponsored ADR compare 12.2×
VTRS Viatris Inc. compare 12.3×
UTHR United Therapeutics Corporation compare 14.7×
NBIX Neurocrine Biosciences, Inc. compare 16.5×
ELAN Elanco Animal Health Incorporated compare 19.7×
RDY Dr. Reddy's Laboratories Ltd compare 22.9×
TEVA Teva Pharmaceutical Industries Ltd. 26.2×
Drug Manufacturers Specialty & Generic industry median 12.2×
Healthcare sector median 8.4×
Market median 10.9×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on TEVA